- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05335252
Dronabinol etter artroskopisk kirurgi
Dronabinol for behandling av postoperativ smerte etter artroskopisk kirurgi: en randomisert pilotforsøk
The purpose of the proposed study is to evaluate the efficacy of dronabinol for postoperative pain after arthroscopic surgery of the knee. The investigators hypothesize that dronabinol will relieve pain, reduce opioid consumption and will result in few negative side effects. If this pilot study shows promising results the investigators will expand the trial to include additional arthroscopic surgeries (hip, shoulder) and other types of orthopaedic surgery.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 3
Kontakter og plasseringer
Studiesteder
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60611
- Northwestern University Feinberg School of Medicine
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
Age 18 years or older
-
Patient who will undergo arthroscopic surgery of the knee including, but not limited to,
- Meniscectomy
- Synovectomy
- Chondroplasty
- Loose body removal
Exclusion Criteria:
-
Patients under age 18 years
-
Patients who cannot provide consent
-
Patients who are pregnant, breast feeding, or are trying to become pregnant during the study period
-
Patients with an allergy to any of the study drugs
-
Patient who are lactose-intolerant
-
Revision surgery
-
Open surgery
-
Comorbidities preventing surgery
-
Patients with a history of mania, depression, or schizophrenia
-
Patients taking any of the following drugs or supplements
- Anticholinergic agents
- Benzodiazepines
- Central nervous system depressants
- Droperidol
- Hydroxyzine
- Levomepromazine or methotrimeprazine
- Monoamine oxidase inhibitors
- Ritonavir
- Selective serotonin reuptake inhibitors
- Sympathomimetics
- St. John's Wort
-
Current diagnosed alcohol or drug abuse
-
Patients who cannot or will not abide by the medication restrictions listed below
Medication restrictions
- Participants must agree to abstain from using recreational or medical marijuana products or cannabidiol (CBD) in any form during the treatment period
- Participants should not drink alcohol or take other drugs while taking the study drug or hydrocodone/acetaminophen
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Dronabinol
Patients will received dronabinol (5mg) twice a day for 7 days in addition to standard pain medication protocol after arthroscopic knee surgery |
5mg 2x daily for 7 days
Andre navn:
|
|
Placebo komparator: Placebo
Patients will received placebo twice a day for 7 days in addition to standard pain medication protocol after arthroscopic knee surgery |
1 caplet 2x daily for 7 days |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Opioid consumption
Tidsramme: up to 7 days post-surgery
|
Count of number of hydrocodone/acetaminophen tablet consumed |
up to 7 days post-surgery
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Pain Visual Analog Scale (VAS)
Tidsramme: up to 7 days post-surgery
|
Scored from 0 (no pain) to 10 (worst possible pain) |
up to 7 days post-surgery
|
|
Patient-Reported Outcomes Measurement Information System (PROMIS) Bank v1.1 - Pain Interference
Tidsramme: up to 21 days post-surgery
|
PROMIS measures generate T-scores. T-scores are standard scores with a mean of 50 and standard deviation of 10 in a reference population (usually U.S. general population). A low score indicates less pain interference (better outcome) and a high score indicates more pain interference (worse outcome). |
up to 21 days post-surgery
|
|
PROMIS Bank v2.0 - Pain Behavior
Tidsramme: up to 21 days post-surgery
|
PROMIS measures generate T-scores. T-scores are standard scores with a mean of 50. A low score indicates less pain (better outcome) and a high score indicates more pain (worse outcome). |
up to 21 days post-surgery
|
|
PROMIS Bank v2.0 - Physical Function
Tidsramme: up to 21 days post-surgery
|
PROMIS measures generate T-scores. T-scores are standard scores with a mean of 50. A low score indicates worse physical functioning and a high score indicates better physical functioning. |
up to 21 days post-surgery
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Vehniah K Tjong, MD, Northwestern Feinberg School of Medicine
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- STU00213383
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .